According to the Zhitong Finance App, Viva Biotech (01873) announced results for the year ended December 31, 2023. The group's revenue was RMB 2,156 billion (same unit), a year-on-year decrease of 9.4%; loss attributable to shareholders was RMB 116 million, a year-on-year narrowing of 78.03%; and a loss of 0.06 yuan per share.

According to the announcement, the decline in revenue was mainly due to (1) the decline in global biomedicine investment in innovative drug research and development and the impact of the Group's strategic contraction on the EFS business; and (2) delays in orders from some CDMO customers.